Method for determining the form of lactic acid in preparations

Through the combination of HPLC detection and specific chromatographic columns, the problem of judging lactic acid morphology in drug preparations is solved, and rapid and accurate lactic acid morphology identification is achieved, ensuring the quality of the drug and saving detection costs.

CN115166071BActive Publication Date: 2024-11-12NKD PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210693260.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-06-17
Publication Date
2024-11-12
Estimated Expiration
2042-06-17

AI Technical Summary

Technical Problem

The prior art is difficult to effectively judge the existence and form of lactic acid in pharmaceutical preparations, especially when other ingredients interfere with it, affecting the quality and stability of the drug.

Method used

Using HPLC detection method, a chromatographic column filled with sulfonated polystyrene divinylbenzene resin was used to determine whether the lactic acid is a single form or a mixture by the chromatographic peak shape of the test sample solution, and the column was judged by the peak shape of the reference sample solution. Applicability and interference situation, combined with acid, alkali and high temperature treatment, determine the existence and form of lactic acid.

Benefits of technology

It realizes rapid and accurate judgment of the existence and form of lactic acid in the drug, avoids interference from auxiliary materials, significantly saves detection time and cost, ensures the quality of the drug, and provides a fast morphological judgment method for the research and development of generic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115166071B_ABST
    Figure CN115166071B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceutical technology, and in particular to a method for determining the presence form of lactic acid in a preparation. The method comprises taking a test solution, performing HPLC detection, and recording a chromatogram; judging the presence form of lactic acid in the test solution according to the shape of the chromatographic peak of the test solution; and the chromatographic column used uses a strong cation exchange resin as a filler. The method of the present invention can realize rapid judgment of the presence form of lactic acid in a drug, is beneficial to the quality control of the drug, can significantly save detection time, and reduce costs. The method of the present invention can also realize automated detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and in particular to a method for determining the existence form of lactic acid in a preparation. Background Art

[0002] Lactic acid is a carboxylic acid with a molecular formula of C3H6O3. It is a carboxylic acid containing a hydroxyl group. In aqueous solution, its carboxyl group releases a proton to produce lactate ions CH3CHOHCOO - Lactic acid is a mixture containing 2-hydroxypropionic acid, its condensation products such as lactoylactic acid, polylactic acid and water.

[0003] Lactic acid can be used as a preservative, disinfectant, pH adjuster, cosolvent and carrier for prodrug preparations in pharmaceutical preparations.

[0004] During the research process of chemical drug formulation development, it was found that in some liquid preparations containing lactic acid excipients, the pH value of the solution will gradually decrease over time during accelerated long-term stability placement, but it will no longer change after decreasing to a certain level, indicating that the condensation product in the lactic acid is hydrolyzed at a certain temperature, causing the pH value to decrease. To ensure the quality of the drug, the presence of lactic acid in the preparation should be focused on during drug formulation development. It can be in the form of a monomer lactic acid content greater than 90%, or in the form of a mixture of 2-hydroxypropionic acid and its condensate. It is suggested that the presence of lactic acid in the drug development process may affect the quality of the product.

[0005] Existing methods are mainly focused on testing the content of lactic acid monomers in drugs, and there is little research on the control of polymers in lactic acid.

[0006] The existing technology refers to L-lactic acid. The National Pharmacopoeia Committee’s draft for public comments controls lactic acid monomers, dimers, trimers, and tetramers under the relevant substances. It is applicable to situations where other ingredients in the prescription, except lactic acid, do not interfere with the inspection of lactic acid monomers, dimers, trimers, and tetramers.

[0007] For other preparations that interfere with lactic acid monomers, dimers, trimers, and tetramers in the prescription, the method in the draft for public comments of the National Pharmacopoeia Committee on L-lactic acid is obviously not applicable. Summary of the invention

[0008] The present invention aims to solve at least one of the above technical problems.

[0009] The present invention provides a method for determining the existence form of lactic acid in a preparation, which can quickly determine the existence form of lactic acid in a medicine.

[0010] A method for determining the form of lactic acid in a preparation, comprising:

[0011] Take the test solution, perform HPLC detection, and record the chromatogram;

[0012] According to the shape of the chromatographic peak of the test solution, the form of lactic acid in the test solution was determined;

[0013] The chromatographic column used uses sulfonated polystyrene divinylbenzene resin as filler.

[0014] According to an embodiment of the present invention, if the chromatographic peak of the test solution is a symmetrical chromatographic peak shape, it indicates that the lactic acid in the test solution is in a single form; if the chromatographic peak of the test solution is an asymmetrical chromatographic peak shape, it indicates that the lactic acid in the test solution exists as a mixture.

[0015] According to an embodiment of the present invention, the single form means that the content of lactic acid monomer in the test solution accounts for 90 wt % or more of the total lactic acid content.

[0016] According to an embodiment of the present invention, the chromatographic column includes a chromatographic column BP-100, a chromatographic column Vertex Sugar-H, a chromatographic column AMINEX HPX-87H, and the like.

[0017] In some specific embodiments, the chromatographic column used is AMINEX HPX-87H (7.8×300 mm, 5 μm).

[0018] The inventors have found that the use of sulfonated polystyrene divinylbenzene resin as a chromatographic column filler can avoid the interference of most auxiliary materials on the form of lactic acid. 18 Under conventional chromatographic conditions, it is impossible to detect monomers, dimers, trimers or tetramers in lactic acid in the presence of interference from excipients, and it is further impossible to determine whether lactic acid exists as a mixture in the test solution.

[0019] According to an embodiment of the present invention, the method for determining the presence form of lactic acid in the preparation further comprises the following steps:

[0020] Take the reference solution, perform HPLC test, and record the chromatogram;

[0021] in,

[0022] 1) The reference solution is a lactate reference solution; judging whether the chromatographic column used can be used for the test according to the peak shape of the chromatographic peak of the reference solution, and / or judging whether the chromatographic peak of the test solution is symmetrical according to the peak shape of the chromatographic peak of the reference solution; or,

[0023] 2) The reference solution is a lactic acid solution; and whether the chromatographic peak of the test solution is symmetrical is determined based on the shape of the chromatographic peak of the reference solution.

[0024] In some embodiments, the chromatographic peak shape of the reference solution is a single peak shape, indicating that the lactic acid therein exists in a monomeric form. The chromatographic peak shape of lactic acid in the HPLC of the test solution that has not been treated with acid, alkali, or high temperature can be further determined. If the test solution has not been treated with acid, alkali, or high temperature, the chromatographic peak shape in the test solution is the true form of lactic acid in the formulation; if the test solution is treated with acid, alkali, or high temperature, the chromatographic peak shape cannot reflect whether the lactic acid in the formulation exists in a monomeric form or in a mixture form.

[0025] In some embodiments, the reference solution is a lactate reference solution (sometimes referred to herein as qualitative solution 1), wherein the lactate can be selected from calcium lactate, sodium lactate, zinc lactate or ferrous lactate, preferably sodium lactate.

[0026] In some embodiments, if the chromatographic peak of the test solution is consistent with the peak shape of the lactate reference solution (qualitative solution 1), it means that the lactic acid in the test solution has been treated with appropriate acid, alkali, or high temperature, or the lactic acid in the preparation formula has been treated before being added to prepare the preparation product.

[0027] The present invention also unexpectedly found that the peak shape of the lactate (preferably sodium lactate) reference solution (qualitative solution 1) can be used to determine whether the chromatographic column used can be used for the present detection. That is, if the peak shape of the lactate (preferably sodium lactate) reference solution (qualitative solution 1) is symmetrical, it means that the chromatographic column used is suitable for the determination of the lactic acid form of the present invention. Among them, the more symmetrical the peak shape is, the more accurate the determination result of the lactic acid form is.

[0028] In addition, whether the chromatographic peak of the test solution is symmetrical can also be judged based on the peak shape of the lactate (preferably sodium lactate) reference solution (qualitative solution 1).

[0029] In some embodiments, the reference solution is a lactic acid solution (sometimes also referred to herein as qualitative solution 2).

[0030] In some embodiments, if the chromatographic peak of the test solution is consistent with the peak shape of the lactic acid solution (qualitative solution 2), it means that the lactic acid in the test solution is directly detected without acid, alkali and high temperature treatment, or the lactic acid in the preparation prescription is directly added to prepare the preparation product.

[0031] According to an embodiment of the present invention, the solvent for preparing the test solution can be selected from water, water-methanol, water-acetonitrile, etc. Water is preferably used as the solvent, which has the advantage of avoiding contact with high temperature, acid, and alkaline environments.

[0032] According to an embodiment of the present invention, the solvent for preparing the reference substance solution may be water.

[0033] According to an embodiment of the present invention, the concentration of the reference solution is in the range of 0.1-1.0 mg / ml, preferably 0.3-0.7 mg / ml, and more preferably 0.5 mg / ml, calculated as lactic acid.

[0034] According to an embodiment of the present invention, the concentration of the test solution can be in the range of 50-150% of the concentration of the reference solution, preferably 100% of the concentration of the reference solution.

[0035] According to an embodiment of the present invention, the HPLC chromatographic conditions are as follows:

[0036] Mobile phase: 0.01-0.03 mol / L sulfuric acid solution, 0.02 mol / L sulfuric acid solution is optional.

[0037] Detector: UV detector

[0038] Detection wavelength: 190-205nm, 195nm optional.

[0039] Flow rate: 0.2-0.4ml / min, optional 0.3ml / min

[0040] Column temperature: 25-40℃, 30℃ optional.

[0041] Injection volume: 20 μl.

[0042] If the method of the present invention determines that the lactic acid in the test solution exists in the form of a mixture, the polymer can be hydrolyzed into monomers by further hydrolysis operations such as acid, alkali, and high temperature for accurate quantification. The chromatographic conditions of the present invention can also be used to achieve quantitative detection of lactic acid.

[0043] The method of the present invention can realize rapid determination of the existing form of lactic acid in drugs, is beneficial to the quality control of drugs, can significantly save detection time, and reduce costs. The method of the present invention can also realize automated detection.

[0044] The method of the present invention also has at least one of the following beneficial effects:

[0045] 1) In the development of chemical generic drugs, accurately determine the existence form of lactic acid in the original formulation and use lactic acid with the same form as the original formulation. This will save the generic drug from having to undergo a long-term 24-month or accelerated 6-month study, thus shortening the generic drug development time.

[0046] 2) The problem that other raw and auxiliary materials in the current method (L-lactic acid related substances in the draft for public comments by the National Pharmacopoeia Committee) interfere with lactic acid and the form of lactic acid cannot be determined is solved.

[0047] 3) By comparing the effects of different degrees of hydrolysis of lactic acid on product quality, this paper provides a new idea for the research and development of drugs containing lactic acid in prescriptions, and further finds prescriptions that are more suitable for production and ensure product quality. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 : Chromatogram of reference substance solution and test solution of Example 1 of the present invention.

[0049] Figure 2 : Chromatogram of the test solution of Comparative Example 1 of the present invention. DETAILED DESCRIPTION

[0050] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.

[0051] Unless otherwise specified, the chromatographic conditions are as follows:

[0052] Chromatographic column: AMINEX HPX-87H (7.8×300mm, 5μm) filled with strong cation exchange resin;

[0053] Mobile phase: 0.02 mol / L sulfuric acid solution;

[0054] Detector: UV detector;

[0055] Detection wavelength: 195nm;

[0056] Flow rate: 0.3ml / min;

[0057] Column temperature: 30°C;

[0058] Injection volume: 20 μl.

[0059] Example 1

[0060] Sodium lactate reference solution (qualitative solution 1): Take an appropriate amount of sodium lactate reference substance and add deionized water to prepare a solution containing 0.5 mg / ml.

[0061] Lactic acid reference solution (qualitative solution 2): Weigh an appropriate amount of lactic acid and add deionized water to prepare a solution containing 0.5 mg / ml.

[0062] Prescription 1: Milrinone injection prescription composition: milrinone, glucose, lactic acid, water for injection.

[0063] name Prescription amount effect Milrinone 10mg Active ingredients lactic acid 10mg pH Adjusters glucose 150mg Osmotic pressure regulator Water for injection 10ml Solvent

[0064] Prescription 2: Ciprofloxacin lactate and sodium chloride injection: ciprofloxacin lactate, lactic acid, hydrochloric acid, sodium chloride, and water for injection.

[0065] name Unit dose effect Ciprofloxacin lactate 0.2g Active ingredients lactic acid 50mg Solvent hydrochloric acid Moderate pH Adjusters Sodium chloride 0.9g Osmotic pressure regulator Water for injection 100ml Solvent

[0066] Prescription 3: Famotidine injection: famotidine, vitamin C, lactic acid, niacinamide, mannitol, sodium hydroxide, and water for injection.

[0067]

[0068]

[0069] Preparation of test solution: Accurately measure appropriate amount of samples of the above three prescriptions respectively, and add deionized water to prepare a solution with a main drug concentration of about 1 mg / ml.

[0070] Accurately measure the above-mentioned reference solution and test solution, inject them into the liquid chromatograph, record the chromatogram, and observe the shape of the lactic acid chromatographic peak. Figure 1 (The horizontal axis is retention time [min], and the vertical axis is response [mAU]).

[0071] The results showed that the peak shape of lactic acid in prescription 1 and prescription 2 was consistent with that of qualitative solution 2, indicating that lactic acid was directly added to the raw material. The peak shape of lactic acid in prescription 3 was consistent with that of qualitative solution 1, indicating that lactic acid was added to the raw material after appropriate treatment or was directly added to the raw material through high-pressure sterilization. Comprehensive prescription 3 was a terminal sterilization process, and lactic acid would be further degraded into monomer form during the process, indicating that lactic acid in this prescription could be directly added to the raw material.

[0072] Comparative Example 1

[0073] The C18 chromatographic conditions of the relevant substances in the draft for public comments of the National Pharmacopoeia Committee of L-lactic acid were used to observe the presence of lactic acid in the test sample of Formula 3 (Famotidine Injection) in Example 1. The raw materials and other excipients in the test sample seriously interfered with lactic acid, and it was impossible to determine the presence of lactic acid in Famotidine Injection (see Figure 2 ).

[0074] In summary, the method of the present invention realizes rapid detection of the form of lactic acid in the product. Since the method can avoid most of the interference of auxiliary materials, it can be used to determine the form of lactic acid in most chemical drugs. It provides a rapid detection method for the amount of lactic acid added in prescription development and the form in which lactic acid is added, which can provide strong data support for prescription development and further ensure the quality of drugs.

[0075] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A method for determining the form of lactic acid in a preparation, characterized in that: include: Take the test solution, perform HPLC detection, and record the chromatogram; According to the shape of the chromatographic peak of the test solution, the form of lactic acid in the test solution was determined; Among them, the chromatographic column used was AMINEX HPX-87H, 7.8×300 mm, with a filler particle size of 5 μm; HPLC chromatographic conditions are as follows: Mobile phase: 0.02 mol / L sulfuric acid solution; Detector: UV detector; Detection wavelength: 195nm; Flow rate: 0.3ml / min; Column temperature: 30°C; Injection volume: 20 μl; If the chromatographic peak of the test solution is a symmetrical peak, it indicates that the lactic acid in the test solution is a single form; if the chromatographic peak of the test solution is an asymmetrical peak, it indicates that the lactic acid in the test solution exists as a mixture; The method for determining the form of lactic acid in the preparation further comprises the following steps: taking a reference solution, performing HPLC detection, and recording a chromatogram; in, 1) The reference solution is a lactate reference solution; judging whether the chromatographic column used can be used for this test based on the peak shape of the chromatographic peak of the reference solution, judging whether the chromatographic peak of the test solution is symmetrical based on the peak shape of the chromatographic peak of the reference solution; the lactate is sodium lactate; or, 2) The reference solution is a lactic acid solution; judging whether the chromatographic peak of the test solution is symmetrical based on the chromatographic peak shape of the reference solution; The concentration of the reference solution is in the range of 0.3-0.7 mg / ml based on lactic acid; the concentration of the test solution is 100% of the concentration of the reference solution; The test samples were selected from milrinone injection, ciprofloxacin lactate and sodium chloride injection, and famotidine injection; If the chromatographic peak of the test solution is consistent with the peak shape of the lactate reference solution, it means that the lactic acid in the test solution has been treated with appropriate acid, alkali, or high temperature, or the lactic acid in the preparation formula has been treated before being added to the preparation product; If the chromatographic peak of the test solution is consistent with the peak shape of the lactic acid solution, it means that the lactic acid in the test solution is directly detected without acid, alkali and high temperature treatment, or the lactic acid in the preparation prescription is directly added to prepare the preparation product.

2. The method for determining the presence form of lactic acid in the preparation according to claim 1, characterized in that: Calculated in terms of lactic acid, the concentration of the reference solution is 0.5 mg / ml.